Lineage Cell The Stock Price, News & Analysis

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) will announce its Q1 2021 financial and operating results on May 13, 2021, after U.S. markets close. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can join the call by dialing the provided numbers or accessing the webcast online. Lineage specializes in allogeneic cell therapies for unmet medical needs, with significant clinical programs in retinal, spinal, and immuno-oncology treatments.

Lineage Cell Therapeutics (LCTX) presented updated interim results from its Phase 1/2a study of OpRegen at the ARVO 2021 conference. The treatment focuses on dry age-related macular degeneration (AMD) with geographic atrophy. Findings showed that 83% of Cohort 4 patients maintained or improved their visual acuity, with some achieving up to +19 letters on the ETDRS chart. The therapy demonstrated significant potential, especially with earlier intervention. No unexpected adverse events were reported, indicating OpRegen's favorable safety profile. This data supports ongoing development of OpRegen as a leading treatment option.

Lineage Cell Therapeutics (NYSE American: LCTX) announced that CEO Brian M. Culley will present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021, at 1:30 p.m. ET. The presentation will be a virtual fireside chat hosted by B. Riley Equity Research. Interested investors can access the live and archived webcast on the Events and Presentations section of Lineage’s website.

Lineage Cell Therapeutics (NYSE American: LCTX) has appointed Dr. Dipti Amin to its Board of Directors as of April 20, 2021. Dr. Amin, a seasoned Non-Executive Director with over 26 years in the pharmaceutical sector, brings extensive experience in clinical research, drug development, and compliance. The company’s Chairman, Al Kingsley, emphasized her ability to significantly advance Lineage’s mission to lead in allogeneic cell transplants. Dr. Amin expressed her enthusiasm about contributing to the company’s growth and guiding its product candidates towards later-stage clinical trials.

Lineage Cell Therapeutics (LCTX) announced a global licensing and collaboration agreement with Immunomic Therapeutics (ITI) to develop a new product candidate aimed at treating glioblastoma multiforme (GBM). This partnership will utilize Lineage's VAC cancer immunotherapy platform and ITI's proprietary Tumor Associated Antigen. Lineage will receive an upfront payment of $2 million and could earn up to $67 million in development and commercial milestones, plus royalties of up to 10% on future sales. This collaboration is expected to diversify Lineage's oncology pipeline and enhance its therapeutic offerings.

Lineage Cell Therapeutics (NYSE: LCTX) announced updated interim results from a Phase 1/2a study of OpRegen®, a cell therapy aimed at treating dry age-related macular degeneration (AMD). The study enrolled 24 patients in four cohorts, assessing safety, tolerability, and preliminary efficacy. Notably, Cohort 4 utilized a new 'thaw-and-inject' formulation, enhancing logistical efficiency. Results will be presented at the 2021 ARVO Annual Meeting on May 6, 2021. Dry AMD affects 85-90% of AMD cases, and no FDA-approved treatments currently exist for this condition.

Lineage Cell Therapeutics (NYSE American: LCTX) announced the compassionate use treatment of a patient with adult-onset vitelliform macular dystrophy (AVMD) using its cell therapy product, OpRegen, at Hadassah-Hebrew University Medical Center. This treatment follows approval from the Israeli Ministry of Health and aims to address the underlying retinal cell damage related to the disease. OpRegen, currently in a Phase 1/2a trial for dry age-related macular degeneration, employs allogeneic retinal pigment epithelium cells. The patient remains under follow-up care post-treatment.

Lineage Cell Therapeutics (NYSE American: LCTX) announced positive interim results from its Phase 1/2a clinical study of OpRegen, a cell therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). In Cohort 4, 75% of patients showed maintained or improved visual acuity, with enhancements of up to +19 letters on an EDTRS chart. Notably, OpRegen has exhibited durability, with some patients demonstrating stable outcomes after over 5 years. The study utilized minimal immunosuppression, with no unexpected adverse events reported, suggesting potential for effective long-term treatment.

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the Benzinga Global Biotech Small Cap conference on March 24, 2021, at 11:50 AM ET. He will also participate in a panel discussion titled “Coming Together to Address Unmet Medical Needs” at 12:50 PM ET. Investors can register for the event in advance at Benzinga's website. The event's webcasts will be accessible on Lineage's Events and Presentations page.